Literature DB >> 17309886

Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach.

Callum G Fraser1, Catriona M Mathew, N Ashley G Mowat, John A Wilson, Francis A Carey, Robert J C Steele.   

Abstract

BACKGROUND: The guaiac faecal occult blood test (gFOBT) has been proved as a screening investigation for colorectal cancer, but has disadvantages. Newer faecal immunochemical tests (FITs) have many advantages, but yield higher positivity rates and are expensive. A two-tier reflex follow-up of gFOBT-positive individuals with a FIT before colonoscopy has been advocated as an efficient and effective approach.
METHODS: A new simple and stable card collection FIT was evaluated.
RESULTS: 1124 individuals who were gFOBT positive were asked to provide samples. 558 individuals participated, 320 refused and 246 did not return samples. No evidence of sampling bias was found. 302 individuals tested FIT negative and 256 tested positive. In the 302 FIT-negative individuals, 2 (0.7%) had cancer and 12 (4.0%) had large or multiple (high-risk) adenomatous polyps. In contrast, of 254 positive individuals, 47 (18.5%) had cancer and 54 (21.3%) had high-risk polyps. 93 (30.8%) of the FIT-negative individuals had a normal colonoscopy, but only 34 (13.4%) of the FIT-positive individuals had no pathology. Sensitivity, specificity, and positive and negative likelihood ratios (and 95% CIs) for cancer were 95.9% (84.8 to 99.3), 59.2% (54.7 to 63.5), 2.35 (2.08 to 2.65) and 0.07 (0.02 to 0.27), and for cancer and high-risk polyps were 87.8% (80.1 to 92.9), 65.3% (60.6 to 69.7), 2.53 (2.19 to 2.93) and 0.19 (0.11 to 0.31), respectively.
CONCLUSIONS: A two-tier reflex screening algorithm, in which gFOBT-positive participants are tested with a FIT, is effective in identifying individuals at high risk of significant colorectal neoplasia. This strategy is transferable across different FIT formats. This approach has been adopted for the Scottish Bowel Screening Programme.

Entities:  

Mesh:

Year:  2007        PMID: 17309886      PMCID: PMC2000260          DOI: 10.1136/gut.2007.119651

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  A demonstration pilot trial for colorectal cancer screening in the United Kingdom: a new concept in the introduction of healthcare strategies.

Authors:  R J Steele; R Parker; J Patnick; J Warner; C Fraser; N A Mowat; J Wilson; F E Alexander; J G Paterson
Journal:  J Med Screen       Date:  2001       Impact factor: 2.136

2.  Lessons from the UK sigmoidoscopy screening trial.

Authors:  David F Ransohoff
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

3.  A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer.

Authors:  S R Cole; G P Young; A Esterman; B Cadd; J Morcom
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

4.  Failure of health care professionals to interpret fecal occult blood tests accurately.

Authors:  Roanne R E Selinger; Sharon Norman; Jason A Dominitz
Journal:  Am J Med       Date:  2003-01       Impact factor: 4.965

5.  Surveillance guidelines after removal of colorectal adenomatous polyps.

Authors:  W S Atkin; B P Saunders
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Immunochemical versus guaiac fecal occult blood tests.

Authors: 
Journal:  Technol Eval Cent Assess Program Exec Summ       Date:  2004-07

Review 7.  Screening tests for colorectal cancer: a menu of options remains relevant.

Authors:  James E Allison; Michael Lawson
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

8.  Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.

Authors:  Graeme P Young; D James B St John; Sidney J Winawer; Paul Rozen
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

9.  Risk of colorectal cancer in adenoma-bearing individuals within a defined population.

Authors:  T J Eide
Journal:  Int J Cancer       Date:  1986-08-15       Impact factor: 7.396

10.  Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.

Authors: 
Journal:  BMJ       Date:  2004-07-05
View more
  8 in total

1.  What is the role of iFOBT in screening for colorectal cancer?

Authors:  David F Ransohoff
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

2.  Fecal immunochemical tests for colorectal cancer screening: a systematic review of accuracy and compliance.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-09-01

3.  Interval cancers in a national colorectal cancer screening programme.

Authors:  Robert Jc Steele; Greig Stanners; Jaroslaw Lang; David H Brewster; Francis A Carey; Callum G Fraser
Journal:  United European Gastroenterol J       Date:  2016-01-06       Impact factor: 4.623

4.  Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.

Authors:  L Sharp; L Tilson; S Whyte; A O'Ceilleachair; C Walsh; C Usher; P Tappenden; J Chilcott; A Staines; M Barry; H Comber
Journal:  Br J Cancer       Date:  2012-02-16       Impact factor: 7.640

5.  Colorectal cancer screening: the northern trust experience.

Authors:  David Neely; William Campbell; Philip Davey; Colin Rodgers; David McCrory
Journal:  Ulster Med J       Date:  2013-09

6.  The influence of blood on the human gut microbiome.

Authors:  Thierry Chénard; Mandy Malick; Jean Dubé; Eric Massé
Journal:  BMC Microbiol       Date:  2020-03-03       Impact factor: 3.605

7.  Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.

Authors:  Linda Sharp; Lesley Tilson; Sophie Whyte; Alan O Ceilleachair; Cathal Walsh; Cara Usher; Paul Tappenden; James Chilcott; Anthony Staines; Michael Barry; Harry Comber
Journal:  BMC Health Serv Res       Date:  2013-03-19       Impact factor: 2.655

Review 8.  Primary and secondary prevention of colorectal cancer.

Authors:  Pedro J Tárraga López; Juan Solera Albero; José Antonio Rodríguez-Montes
Journal:  Clin Med Insights Gastroenterol       Date:  2014-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.